The 10 drugs that cost Medicare Part D the most in 2018, according to a Moody’s Investors Service report:
- Eliquis (Bristol-Myers Squibb/Pfizer) — $4.99 billion
- Revlimid (Bristol-Myers Squibb) — $4.06 billion
- Xarelto (Johnson & Johnson/ Bayer) — $3.36 billion
- Januvia (Merck) — $3.23 billion
- Lyrica (Pfizer) — $2.95 billion
- Advair Diskus (GlaxoSmithKline) — $2.39 billion
- Humira Pen (AbbVie) — $2.39 billion
- Lantus Solostar (Sanofi) — $2.37 billion
- Imbruvica (AbbVie/Johnson & Johnson) — $1.87 billion
- Symbicort (AstraZeneca) — $1.75 billion
More articles on pharmacy:
CVS offering emergency prescriptions in Puerto Rico
IPO of joint venture with Pfizer not discussed, GlaxoSmithKline says
Civica Rx inks deal to create its own drugs
